The FDA clears GL-IL2-138, a groundbreaking oral drug modulating natural IL-2, set to revolutionize treatment in oncology.

BiomX Inc. (AMEX:PHGE) saw its stock jump 60% after announcing the commencement of patient dosing in its Phase 2b clinical ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

PYPD PolyPid Ltd. (NASDAQ:PYPD) is a late clinical stage biopharma company focused on developing locally administered, prolonged-release therapeutics using its proprietary Polymer-Lipid Encapsulation ...

Patients with knee osteoarthritis who received metformin demonstrated significant reductions in knee pain and increased ...

Takeda announces positive results from two pivotal phase 3 studies of oveporexton in narcolepsy type 1: Osaka Wednesday, July 16, 2025, 16:30 Hrs [IST] Takeda, a global company fo ...

An FDA-funded clinical trial found even modest CBD use triggered elevated liver enzymes in some healthy adults, raising ...

At two doses, baxdrostat demonstrated significant reduction in mean seated systolic BP vs. placebo at 12 weeks among patients ...